Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genentech, Inc. v. Amgen Inc.
Case Number:
1:18-cv-00924
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 03, 2020
Fed. Circ. Calls Biotech's Last-Minute Bid An 'Ambush'
Genentech was on the receiving end of an upbraiding Tuesday after the Federal Circuit sensed the biotech giant had come down too harshly on the Delaware federal judge who denied its bid to block a biosimilar of a blockbuster cancer drug.
-
July 22, 2019
Amgen, Allergan Launch 2 Biosimilars With Court's Blessing
Amgen and Allergan have started selling their biosimilar versions of Genentech's blockbuster cancer treatments Avastin and Herceptin in the U.S., announcing the launch immediately after a Delaware federal judge refused to block the sales.